Adaptimmune Therapeutics plc (ADAP) provided updated data from its Phase 1 ADP-A2AFP trial for patients with liver cancer. The data showed significant antitumor activity with the first-generation product targeting AFP that is encouraging for the potential of cell therapy for the treatment of liver cancer in these heavily pre-treated patients with late-stage disease.
The company reported a complete response in one patient, and tumor reductions with stable disease that has lasted more than 16 weeks in two patients as well as disease control in most patients at the target dose.
Bruno Sangro of Clinica Universidad de Navarra said the first results from the cell therapy trial were of great interest since they indicate obvious antitumor activity in some patients. The treatment has generally been safely applied even to cirrhotic patients.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.